Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation

Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):59-61. doi: 10.1053/srao.2002.31375.

Abstract

For limited-stage small cell lung cancer, twice-daily radiation with concurrent chemotherapy improves survival rate, but has dose-limiting esophageal toxicity. The authors studied 34 patients treated with amifostine in an attempt to decrease the incidence and grade of esophagitis. The results indicate that there was no reduction in toxicity, but the authors were able to maintain the high complete response rate that had been reported previously. These results differ from the use of amifostine in non-small cell lung cancer in which there is the observation of esophageal protection.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Amifostine / adverse effects
  • Amifostine / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Small Cell / drug therapy
  • Carcinoma, Small Cell / radiotherapy*
  • Combined Modality Therapy
  • Dose-Response Relationship, Radiation
  • Esophagitis / pathology
  • Esophagitis / prevention & control
  • Esophagus / pathology
  • Esophagus / radiation effects*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / radiotherapy*
  • Radiation Injuries / prevention & control
  • Radiation-Protective Agents / adverse effects
  • Radiation-Protective Agents / therapeutic use*

Substances

  • Antineoplastic Agents
  • Radiation-Protective Agents
  • Amifostine